Korea Exchange · Healthcare
Samsung Biologics stock from India: price, numbers and tax
Samsung Biologics (207940) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Samsung Biologics at a glance
- Price
- ₩1,219,000.00-₩58,000.00 (4.54%)
- Market cap
- ₩56.43T
- Day range
- ₩1,218,000.00 – ₩1,274,000.00
- P/E
- 28.42
- Dividend yield
- None
- Volume
- 101.61K
- 1 month
- -14.84%
- 6 months
- -23.72%
- YTD
- -28.08%
- 1 year
- -21.42%
- 5 years
- -4.48%
Samsung Biologics statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩4.6T | ₩3.5T | ₩3.7T | ₩3.0T | ₩1.6T |
| Gross profit | ₩2.5T | ₩1.7T | ₩1.8T | ₩1.4T | ₩785.0B |
| Operating income | ₩2.1T | ₩1.3T | ₩1.1T | ₩983.6B | ₩537.3B |
| Net income | ₩1.8T | ₩1.1T | ₩857.7B | ₩798.1B | ₩393.6B |
| Earnings per share | ₩38,588.00 | ₩23,402.00 | ₩18,528.00 | ₩17,592.00 | ₩9,050.12 |
| EBITDA | ₩2.8T | ₩2.0T | ₩1.7T | ₩1.4T | ₩737.8B |
| Total assets | ₩11.1T | ₩17.3T | ₩16.0T | ₩16.6T | ₩8.0T |
| Total debt | ₩928.2B | ₩1.5T | ₩1.9T | ₩2.5T | ₩1.3T |
| Cash and short-term investments | ₩1.5T | ₩1.3T | ₩2.1T | ₩3.2T | ₩1.4T |
| Shareholders' equity | ₩7.5T | ₩10.9T | ₩9.8T | ₩9.0T | ₩5.0T |
| Operating cash flow | ₩2.2T | ₩1.7T | ₩1.7T | ₩953.0B | ₩454.6B |
| Free cash flow | ₩856.1B | ₩281.7B | ₩560.9B | −₩56.2B | ₩33.4B |
| Capital expenditure | −₩1.4T | −₩1.4T | −₩1.1T | −₩1.0T | −₩421.2B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Celltrion | 068270.KS | ₩179,600.00 | ₩41.19T |
| Biocon | BIOCON.NS | $350.00 | $478.17B |
| WuXi AppTec | 603259.SS | CNH 162.00 | CNH 400.67B |
| Prestige BioPharma | 950210.KS | ₩5,960.00 | ₩358.17B |
| WuXi Biologics (Cayman) | 2269.HK | HK$54.10 | HK$224.17B |
| WuXi XDC Cayman | 2268.HK | HK$82.25 | HK$104.16B |
| Genscript Biotech | 1548.HK | HK$40.70 | HK$88.92B |
| Pharmaron Beijing | 300759.SZ | $43.75 | $64.63B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Samsung Biologics from India
What Samsung Biologics does
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Samsung Biologics operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Samsung Biologics shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.